Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

Gelatinase B (−1562C/T) polymorphism in tumor progression and invasion of breast cancer

Authors: P. Chiranjeevi, K. Mrudula Spurthi, N. Santhoshi Rani, G. Rajesh Kumar, T. Mohini Aiyengar, M. Saraswati, G. Srilatha, G. Kishore Kumar, Sudha Sinha, C. Sanjeeva Kumari, B. Nagarjuna Reddy, S. Vishnupriya, H. Surekha Rani

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

Matrix metalloproteinases (MMPs) play an important role in breast cancer tumor invasion and progression. MMP-9 is a member of the MMP family and is also known as Gelatinase B or type IV collagenases (92 kDa) and possesses proteolytic activity against type IV collagen, a major component of the basement membrane. Our study aims to examine the association of Gelatinase B (−1562C > T) promoter polymorphism with breast cancer invasion and progression. The study involves 200 breast cancer patients and age-matched 191 healthy controls. The SNP-1562C > T (rs3918242) in MMP-9 promoter region was examined by allele-specific polymerase chain reaction and gel electrophoresis. The genotypes were determined and compared between patients and controls, and the influence of the polymorphism on clinicopathological data was analyzed. The T allele of the -1562C > T MMP-9 polymorphism was detected more frequently in breast cancer patients than controls (p < 0.001). Our results suggest the clinical importance of MMP-9 gene polymorphism (−1562C > T) in breast cancer patients. The study may also help in identifying individuals at risk of developing breast cancer.
Literature
1.
2.
Gaurav A, Pooja R, Ernesto R, Sa'nchez F, Jorge Carrasco R'n, Juan Manuel C, et al. Breast cancer care in developing countries. World J Surg. 2009;33:2069–76.CrossRef
3.
4.
Byrne C, Brinton LA, Haile RW, Schairer C. Heterogeneity of the effect of family history on breast cancer risk. Epidemiology. 1991;2:276–84.PubMedCrossRef
5.
Smith P, McGuffog L, Douglas F, Easton, et al. A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer. 2006;45:646–55.PubMedCentralPubMedCrossRef
6.
Pakseresht S, Ingle GK, Bahadur AK, Ramteke VK, Singh MM, Garg S, et al. Risk factors with breast cancer among women in Delhi. Indian J Cancer. 2009;46:132–8.PubMedCrossRef
7.
Althuis DM, Dozier JM, Anderson FW, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality. Int J Epidemiol. 1973–1997; 34:405–12.
8.
Maller O, Martinson H, Schedin P. Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland. J Mammary Gland Biol Neoplasia. 2010;15:301–18.PubMedCrossRef
9.
10.
Forget MA, Desrosiers RR, Beliveau R. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol. 1999;77:465–80.PubMedCrossRef
11.
Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995;55:1856–62.PubMed
12.
13.
Jed F. Fisher, Shahriar Mobashery. Recent advances in MMP inhibitor design, Cancer Metastasis Rev.2006; 115–36.
14.
Ajay Kumar Chaudhary, Mamta Singh, Alok C Bharti, Kamlesh Asotra, Shanthy Sundaram and Ravi Mehrotra. Genetic polymorphisms of matrix metalloproteinases and their inhibitors in potentially malignant and malignant lesions of the head and neck, J Biol Chem. 2010; 17–10.
15.
16.
Jones JL, Walker RA. Control of matrix metalloproteinase activity in cancer. J Pathol. 1997;183:377–9.PubMedCrossRef
17.
McDonnell S, Navre M, Coffey Jr RJ, Matrisian LM. Expression and localization of matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog. 1991;4:527–33.PubMedCrossRef
18.
Tu HF, Wu CH, Kao SY, Liu CJ, Liu TY, Lui MT. Functional −1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users. J Oral Pathol Med. 2007;36:409–14.PubMedCrossRef
19.
Wu J, Zhang L, Luo H, Zhu Z, Zangh C, Hou Y. Association of matrix metalloproteinases-9 gene polymorphisms with genetic susceptibility to esophageal squamous cell carcinoma. DNA Cell Biol. 2008;27:553–7.PubMedCrossRef
20.
21.
Kallakury BV et al. Increased expression of Matrix metalloproteinase 2 & 9 and tissue inhibitors of matrix metalloproteinase 1 & 2 correlates with poor prognostic variables in renal cell carcinoma. Clin Cancer Res. 2001;7:3113–9.PubMed
22.
Baker EA, Leaper DJ. Measuring gelatinase activity in colorectal cancer. Eur J Surg Oncol. 2002;28:24–9.PubMedCrossRef
23.
Tanioka Y, Yoshida T, Yagawa T, Saiki Y, Takeo S, Harada T, et al. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer. 2003;89:2116–21.PubMedCentralPubMedCrossRef
24.
Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U, Uray M. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol. 2003;24:417–20.PubMed
25.
Sakata K, Satoh M, Someya M, Asanuma H, Nagakura H, Oouchi A, et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer. 2004;100:356–65.PubMedCrossRef
26.
27.
Raković MŽA, Stanković A. Allele-specific detection of C-1562T polymorphism in the matrix metalloproteinase-9 gene: genotyping by MADGE. Clin Biochem. 2006;39:630–2.PubMedCrossRef
28.
McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 2000;6:149–56.PubMedCrossRef
29.
Venkateshwari AK, Sri M, Krishnaveni D, Pratibha N, Vidyasagar A, Jyothy A. Role of plasma MMP 9 levels in the pathogenesis of chronic pancreatitis. Ind J Clin Biochem. 2011;26:136–9.CrossRef
30.
Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and −9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 2005;87:287–97.PubMedCrossRef
31.
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathological features and survival. Clin Med Res. 2009;7:4–13.PubMedCentralPubMedCrossRef
32.
Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998;52:261–88.PubMedCrossRef
33.
Rose DP, Royak-Schaler R. Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect Prev. 2001;25:16–31.PubMed
34.
Zhang S, Li L, Lin JY, Lin H. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol. 2003;9:899–04.PubMed
35.
Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999;99:1788–94.PubMedCrossRef
36.
Baker EA, Leaper DJ. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer. 2003;39:981–8.PubMedCrossRef
37.
Zhou Y, Chunyuan Y, Miao X, Tan W, Liang G, Xiong P, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis. 2004;25:399–04.PubMedCrossRef
38.
Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol. 2000;10:415–33.PubMedCrossRef
39.
Srivastava P, Mandhani A, Kapoor R, Mittal RD. Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort. Ann Surg Oncol. 2010;17:3068–75.PubMedCrossRef
40.
Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J, et al. Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat. 2006;95:65–72.PubMedCrossRef
41.
Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, et al. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res. 2006;26:3579–83.PubMed
42.
Ishimaru H, Kageyama Y, Hayashi T, Nemoto T, Eishi Y, Kihara K. Expression of matrix metalloproteinase-9 and bombesin/gastrin-releasing peptide in human prostate cancers and their lymph node metastases. Acta Oncol. 2002;41:289–96.PubMedCrossRef
43.
Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996;271:10672–80.PubMedCrossRef
44.
Shibao TK, Tsurudome Y, Hirata K, Nagata N, Itoh H. Lymphatic microvessel density is an independent prognostic factor in colorectal cancer. Dis Colon Rectum. 2007;50:308–14.PubMedCrossRef
45.
Shu Y. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res. 2006;69:636–45.CrossRef
Metadata
Title
Gelatinase B (−1562C/T) polymorphism in tumor progression and invasion of breast cancer
Authors
P. Chiranjeevi
K. Mrudula Spurthi
N. Santhoshi Rani
G. Rajesh Kumar
T. Mohini Aiyengar
M. Saraswati
G. Srilatha
G. Kishore Kumar
Sudha Sinha
C. Sanjeeva Kumari
B. Nagarjuna Reddy
S. Vishnupriya
H. Surekha Rani
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1181-5

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue

Research Article

Analysis of the association of interleukin-17 gene polymorphisms with gastric cancer risk and interaction with Helicobacter pylori infection in a Chinese population

Research Article

Antitumor activity of a sulfated polysaccharide from Enteromorpha intestinalis targeted against hepatoma through mitochondrial pathway

Research Article

The prognostic value of elevated ezrin in patients with osteosarcoma

Research Article

The combination of TRPM8 and TRPA1 expression causes an invasive phenotype in lung cancer

Research Article

CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion

Research Article

Quantitative assessment of the association between XPC Lys939Gln polymorphism and cutaneous melanoma risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits